Zacks Research Upgrades Alterity Therapeutics (NASDAQ:ATHE) to “Hold”

Alterity Therapeutics (NASDAQ:ATHE) was upgraded by Zacks Research to a “hold” rating in a report released on Wednesday,Zacks.com reports.

ATHE has been the subject of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research report on Monday, April 20th. LADENBURG THALM/SH SH assumed coverage on Alterity Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $10.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.00.

Alterity Therapeutics Trading Down 5.1%

Shares of NASDAQ ATHE opened at $4.88 on Wednesday. The firm’s fifty day moving average is $4.31 and its two-hundred day moving average is $3.69. Alterity Therapeutics has a 52-week low of $4.14 and a 52-week high of $350.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Alterity Therapeutics stock. Citadel Advisors LLC acquired a new stake in shares of Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned about 0.25% of Alterity Therapeutics as of its most recent SEC filing. Institutional investors own 2.14% of the company’s stock.

Alterity Therapeutics Company Profile

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.